CO2021004704A2 - Compuestos para tratar ciertas leucemias - Google Patents
Compuestos para tratar ciertas leucemiasInfo
- Publication number
- CO2021004704A2 CO2021004704A2 CONC2021/0004704A CO2021004704A CO2021004704A2 CO 2021004704 A2 CO2021004704 A2 CO 2021004704A2 CO 2021004704 A CO2021004704 A CO 2021004704A CO 2021004704 A2 CO2021004704 A2 CO 2021004704A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- abl1
- compounds
- abelson
- bcr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos, preferiblemente compuestos que inhiben la actividad enzimática de tirosina quinasa de una proteína seleccionada de la proteína Abelson (ABL1), proteína relacionada con Abelson (ABL2), o una proteína quimérica BCR-ABL1, composiciones de las mismas, y métodos de su preparación, y métodos para inhibir la actividad enzimática de tirosina quinasa de una proteína seleccionada de la proteína Abelson (ABL1), proteína relacionada con Abelson (ABL2), o una proteína quimérica BCR-ABL1, y métodos para tratar enfermedades en donde la modulación de la actividad de BCR-ABL1 previene, inhibe, o mejora la patología y/o sintomatología de la enfermedad.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862733029P | 2018-09-18 | 2018-09-18 | |
US201962816637P | 2019-03-11 | 2019-03-11 | |
US201962889929P | 2019-08-21 | 2019-08-21 | |
PCT/US2019/051567 WO2020061086A2 (en) | 2018-09-18 | 2019-09-17 | Compounds for treating certain leukemias |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021004704A2 true CO2021004704A2 (es) | 2021-04-30 |
Family
ID=69774840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0004704A CO2021004704A2 (es) | 2018-09-18 | 2021-04-15 | Compuestos para tratar ciertas leucemias |
Country Status (17)
Country | Link |
---|---|
US (2) | US10889571B2 (es) |
EP (1) | EP3852745A4 (es) |
JP (1) | JP2022501429A (es) |
KR (1) | KR20210061377A (es) |
CN (3) | CN115448908A (es) |
AU (1) | AU2019342102A1 (es) |
BR (1) | BR112021004051A2 (es) |
CA (1) | CA3110576A1 (es) |
CL (1) | CL2021000637A1 (es) |
CO (1) | CO2021004704A2 (es) |
IL (1) | IL281427A (es) |
MA (1) | MA53664A (es) |
MX (2) | MX2021003093A (es) |
PE (1) | PE20211644A1 (es) |
SG (1) | SG11202102367TA (es) |
TW (1) | TWI826525B (es) |
WO (1) | WO2020061086A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113490668A (zh) | 2018-10-05 | 2021-10-08 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
CN113784955A (zh) | 2019-03-11 | 2021-12-10 | 因弗拉克斯有限责任公司 | 作为C5a受体调节剂的稠合哌啶基双环和相关化合物 |
WO2021018194A1 (en) * | 2019-07-29 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Heterocyclic compounds as bcr-abl inhibitors |
BR112023017612A2 (pt) * | 2021-03-03 | 2023-12-05 | Terns Pharmaceuticals Inc | Compostos agonistas do receptor beta do hormônio da tireoide |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ508413A (en) * | 1998-05-22 | 2003-08-29 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
PE20061378A1 (es) * | 2005-04-20 | 2006-12-03 | Smithkline Beecham Corp | INHIBIDORES DE LA ACTIVIDAD DE Akt |
PE20080888A1 (es) * | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
-
2019
- 2019-09-17 JP JP2021539486A patent/JP2022501429A/ja active Pending
- 2019-09-17 CA CA3110576A patent/CA3110576A1/en active Pending
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/en unknown
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 CN CN202210969394.6A patent/CN115448908A/zh active Pending
- 2019-09-17 AU AU2019342102A patent/AU2019342102A1/en active Pending
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/en active Pending
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko unknown
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
- 2019-09-17 CN CN202210968772.9A patent/CN115215838A/zh active Pending
-
2021
- 2021-03-11 IL IL281427A patent/IL281427A/en unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US20240101536A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240101536A1 (en) | 2024-03-28 |
CN115215838A (zh) | 2022-10-21 |
MA53664A (fr) | 2022-05-04 |
AU2019342102A1 (en) | 2021-03-11 |
TWI826525B (zh) | 2023-12-21 |
KR20210061377A (ko) | 2021-05-27 |
WO2020061086A3 (en) | 2020-07-23 |
PE20211644A1 (es) | 2021-08-24 |
EP3852745A2 (en) | 2021-07-28 |
BR112021004051A2 (pt) | 2021-05-25 |
EP3852745A4 (en) | 2022-05-04 |
JP2022501429A (ja) | 2022-01-06 |
CN115448908A (zh) | 2022-12-09 |
IL281427A (en) | 2021-04-29 |
WO2020061086A2 (en) | 2020-03-26 |
US10889571B2 (en) | 2021-01-12 |
US20200087283A1 (en) | 2020-03-19 |
CL2021000637A1 (es) | 2021-10-01 |
CA3110576A1 (en) | 2020-03-26 |
MX2021003093A (es) | 2021-05-12 |
MX2023007714A (es) | 2023-07-10 |
CN112770745B (zh) | 2022-09-02 |
TW202024037A (zh) | 2020-07-01 |
SG11202102367TA (en) | 2021-04-29 |
CN112770745A (zh) | 2021-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021004704A2 (es) | Compuestos para tratar ciertas leucemias | |
MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
CR20210387A (es) | Inhibidores de kif18a | |
EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
UY38613A (es) | Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos | |
EA200901211A1 (ru) | Антигены белка с5 и их применение | |
EA201790660A1 (ru) | Ингибитор киназ | |
EA201490542A1 (ru) | Соединения и композиции в качестве pdgfr киназных ингибиторов | |
BR112018069023A2 (pt) | métodos de tratamento de doenças colestáticas | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
DOP2020000252A (es) | Inhibidores de proteina tirosina fosfatasa y sus métodos de uso | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
BR112022007612A2 (pt) | Inibidores de raf quinases | |
AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
MD3728207T2 (ro) | Chinazolinone ca inhibitori PARP14 | |
EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
BRPI0912475B8 (pt) | compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
EA201892284A1 (ru) | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств | |
EA202091937A1 (ru) | Новые способы разведения и контролируемого высвобождения агентов биологического контроля | |
BR112022001270A2 (pt) | Compostos inibidores | |
ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
TN2019000106A1 (en) | Novel compounds for treating parasitic disease |